Drug intelligence / Profile preview

granulocyte-macrophage colony-stimulating factor DNA

Development stage
Phase 1
Modality
Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intradermal, Intramuscular, Subcutaneous
01

Overview

Granulocyte-macrophage colony-stimulating factor DNA refers to **DNA plasmids or constructs encoding the protein GM-CSF**, intended to induce in vivo expression of GM-CSF following delivery (often as gene therapy, genetic vaccine, or as an adjuvant to vaccination). GM-CSF is a cytokine that stimulates the production, differentiation, and activation of granulocytes and macrophages from hematopoietic precursors, enhancing both innate and adaptive immunity. GM-CSF DNA has been used as a direct immunostimulatory agent, as a genetic adjuvant in DNA vaccines (for example, co-delivery of GM-CSF DNA with tumor antigen DNA for cancer immunotherapy), or to augment dendritic cell responses for enhanced antigen presentation. Mechanistically, expressed GM-CSF binds to granulocyte-macrophage colony-stimulating factor receptor on target hematopoietic cells, promoting proliferation, activation, and enhanced immune response, including stimulation of neutrophil, monocyte, macrophage, and dendritic cell populations[1][2][4]. Clinical data exists for use of GM-CSF DNA as a genetic adjuvant (often via epidermal or intramuscular gene delivery, e.g. “gene gun” or electroporation) in cancer vaccine immunotherapy[4].

Other names
GM-CSF DNAGM-CSF geneGM-CSF cDNACSF2 DNACSF-2 DNACSF 2 DNAgranulocyte-macrophage colony stimulating factor DNAGM-CSF plasmid DNA
02

Targets

CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on granulocyte-macrophage colony-stimulating factor DNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on granulocyte-macrophage colony-stimulating factor DNA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call